Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials-Reference-Cited by-同舟云学术

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Published:2017-10-26 Issue:3 Volume:20 Page:620-628
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Jabbour Serge¹^ORCID,Seufert Jochen²,Scheen Andre³^ORCID,Bailey Clifford J.⁴,Karup Cathrina⁵,Langkilde Anna M.⁶

Affiliation:

1. Department of Endocrinology, Sidney Kimmel Medical College at Thomas Jefferson University; Philadelphia Pennsylvania

2. Division of Endocrinology and Diabetology, Department of Internal Medicine II; University Hospital of Freiburg, Medical Faculty, University of Freiburg; Freiburg Germany

3. Department of Medicine, University of Liège; Liège Belgium

4. School of Life and Health Sciences, Aston University; Birmingham UK

5. Department of AZ Global Regulatory Affairs, Patient Safety and QA (GRAPSQA), AstraZeneca Gothenburg; Mölndal Sweden

6. Department of R&D; AstraZeneca Gothenburg; Mölndal Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13124/fullpdf

Reference37 articles.

1. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of Type-2 diabetes: a drug class overview;Mosley;P T,2015

4. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus;Komoroski;Clin Pharmacol Ther,2009

5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus;Scheen;Drugs,2015

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

2. Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome;Advances in Therapy;2024-07-03

3. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study;American Journal of Cardiovascular Drugs;2024-04-30

4. An Overview of Dapagliflozin;International Journal of Innovative Science and Research Technology (IJISRT);2024-04-30

5. Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction;Journal of Cardiovascular Development and Disease;2024-04-19